Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Doximity, Inc. (DOCS) SEC filings page provides access to the company’s official regulatory disclosures as a New York Stock Exchange–listed issuer. Doximity files annual, quarterly, and current reports that describe its financial condition, results of operations, governance matters, and material events affecting the business.
In its filings and related press releases, Doximity presents condensed consolidated balance sheets, statements of operations, and statements of cash flows, along with discussions of non-GAAP financial measures. The company explains how it calculates metrics such as non-GAAP gross profit, non-GAAP net income, adjusted EBITDA, and free cash flow, and provides reconciliations to GAAP results. These documents allow readers to see how Doximity evaluates its performance beyond standard accounting measures.
Current reports on Form 8-K for DOCS include items such as quarterly earnings announcements, changes in executive roles, annual meeting voting results, and legal developments. For example, Doximity has filed 8-Ks to furnish earnings press releases, to report the outcomes of its annual meeting of stockholders, to disclose changes in its general counsel and related roles, and to describe a securities litigation settlement agreement that remains subject to court approval and other customary conditions.
Through its proxy materials and related filings, Doximity also reports on corporate governance topics, including the election of directors, ratification of its independent registered public accounting firm, and advisory votes on executive compensation. Voting results, including the participation of Class A and Class B common stock, are detailed in these documents.
On this page, AI-powered tools can summarize lengthy DOCS filings, highlight key sections on revenue trends, profitability, cash flows, and risk disclosures, and surface notable items such as settlement agreements or executive transitions. Users can quickly review quarterly reports, annual reports, and Form 4 and other transaction-related filings, while relying on real-time updates from the SEC’s EDGAR system to follow new disclosures from Doximity, Inc.
DOCS: A stockholder filed a Form 144 notice to sell 2,000 shares of common stock with an aggregate market value of $132,880. The filing lists Morgan Stanley Smith Barney as broker, an approximate sale date of November 3, 2025, and NYSE as the exchange.
The shares were acquired via a stock option exercise on November 3, 2025 for cash. Recent activity shows sales of 2,000 shares on October 1, 2025 for $140,020 and 2,000 shares on September 2, 2025 for $133,140. Shares outstanding were 136,400,248.
Doximity, Inc. (DOCS): A director reported multiple transactions on 10/10/2025. The insider exercised 5,000 stock options at an exercise price of $2.21, converted 5,000 shares of Class B Common Stock into Class A Common Stock, and sold 5,000 Class A shares at an average price of $70.84 pursuant to a Rule 10b5-1 trading plan adopted on February 26, 2025.
Following the transactions, the insider reported 19,839 shares of Class A Common Stock held directly. The filing notes that each share of Class B Common Stock is convertible into one share of Class A Common Stock at the holder’s option, and also outlines additional automatic conversion conditions.
Doximity, Inc. (DOCS) insider filing notifies a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $354,200.00, scheduled for 10/10/2025 on the NYSE. The shares were acquired the same day by stock option exercise and paid in cash. The filing also discloses three earlier sales by the same seller totaling 15,000 shares in 07/11/2025, 08/08/2025, and 09/12/2025 with gross proceeds of $300,200.00, $315,000.00, and $352,500.00 respectively.
The signer affirms they are unaware of undisclosed material adverse information and, by submitting Form 144, is complying with Rule 144 notification requirements for proposed resale of restricted or control securities.
Doximity insiders reported coordinated transactions on 10/01/2025. Reporting person Kira Wampler, a director, sold 2,000 shares of Class A common stock at $70.01 and concurrently acquired 2,000 shares through conversion/exercise activity tied to outstanding Class B shares and stock options. After these transactions the reporting person beneficially owned 19,839 shares of Class A common stock and 466,700 shares of Class B common stock (equivalent to Class A on conversion). The sale executed under a pre-existing Rule 10b5-1 plan adopted on 11/12/2024, and the stock option exercised carries a $1.54 exercise price with a 06/09/2030 expiration for the vested portion.
Form 144 notice for Doximity, Inc. (DOCS): The filer reports a proposed sale of 2,000 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $140,020.00, expected to sell on 10/01/2025 on the NYSE. The securities were acquired on 10/01/2025 by stock option exercise and paid in cash. The filing also discloses three prior sales by the same person in the past three months: 2,000 shares on 09/02/2025 for $133,140.00, 2,000 shares on 08/01/2025 for $114,180.00, and 2,000 shares on 07/01/2025 for $121,920.00. The notice includes the standard Rule 144 signature representation regarding material nonpublic information.
Timothy S. Cabral, a director of Doximity, Inc. (DOCS), reported transactions on 09/24/2025 showing conversions, a sale under a pre-established trading plan, and option activity. He converted 20,000 shares of Class B into Class A common stock and simultaneously sold 20,000 shares at $75 per share pursuant to a Rule 10b5-1 plan adopted on February 13, 2025, leaving 3,221 shares of Class A common stock beneficially owned. The filing also reports exercise/vesting-related option activity for 20,000 stock options with a $2.21 exercise price and references customary conversion terms for Class B shares.
Form 144 filing for Doximity, Inc. (DOCS) shows a proposed sale of 20,000 common shares through Morgan Stanley Smith Barney on 09/24/2025 with an aggregate market value of $1,500,000. The shares were acquired via a stock option exercise on 09/24/2025 and paid for in cash. The filing lists 187,299,459 shares outstanding for the class. The notice also discloses prior sales by the same person, Timothy Cabral: 6,360 shares on 09/02/2025 for $421,655.28, 20,000 shares on 08/15/2025 for $1,275,566.00, and 10,000 shares on 06/25/2025 for $600,000. The filer certifies they are not aware of any undisclosed material adverse information.
Doximity director Benjamin Regina M. reported transactions on 09/12/2025. The Form 4 shows conversion and movements among Class A and Class B common stock and option activity. The reporting person acquired 5,000 shares of Class A common stock via conversion and exercised a stock option providing the right to buy 5,000 shares at $2.21. Concurrently, 5,000 shares of Class A common stock were sold under a Rule 10b5-1 trading plan at a price of $70.50 per share. After these transactions the reporting person beneficially owned 19,839 shares of Class A and 356,138 shares of Class B common stock (Class B converts 1:1 to Class A).
Form 144 filed for DOCS: Proposed sale of 5,000 common shares on 09/12/2025 through Morgan Stanley Smith Barney LLC with an aggregate market value of $352,500. The filing states these 5,000 shares were acquired and paid for on 09/12/2025 via a stock option exercise and paid in cash. The filing reports the issuer's total shares outstanding as 187,299,459.
The notice also lists three prior sales by Regina M Benjamin in the past three months: 5,000 shares on 08/08/2025 for $315,000, 5,000 shares on 07/11/2025 for $300,200, and 10,000 shares on 06/25/2025 for $600,000. The filing does not provide the issuer name or filer CIK in the visible fields.
Timothy S. Cabral, a director of Doximity, Inc. (DOCS), reported the automatic sale of 6,360 shares of Class A common stock on 09/02/2025 at a weighted-average price of $66.2981 per share pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. After the reported transactions, Mr. Cabral beneficially owned 3,221 shares of Class A common stock. The filing was signed by an attorney-in-fact on 09/04/2025 and the filer notes the sale prices ranged from $65.83 to $66.64 per share.
The Form 4 discloses that the sales occurred automatically under the established trading plan and the reporting person will provide transaction-level price details upon request.